



**HAL**  
open science

## Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Stéphane Culine, Valentin Harter, Gwenaëlle Gravis, Aude Fléchon, Christine Chevreau, Hakim Mahammedi, Brigitte Laguerre, Aline Guillot, Florence Joly, Sophie Abadie-Lacourtoisie, et al.

► **To cite this version:**

Stéphane Culine, Valentin Harter, Gwenaëlle Gravis, Aude Fléchon, Christine Chevreau, et al.. Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. *Clinical Genitourinary Cancer*, 2021, 19 (6), pp.554-562. 10.1016/j.clgc.2021.08.005 . hal-03625944

**HAL Id: hal-03625944**

**<https://hal.science/hal-03625944v1>**

Submitted on 8 Jan 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

## **Chemotherapy for muscle-invasive bladder cancer: impact of cisplatin delivery on renal function and local control rate in the randomized phase III VESPER (GETUG-AFU V05) trial**

Stéphane Culine,<sup>1</sup> Valentin Harter,<sup>2</sup> Gwenaëlle Gravis,<sup>3</sup> Aude Fléchon,<sup>4</sup>  
Christine Chevreau,<sup>5</sup> Hakim Mahammedi,<sup>6</sup> Brigitte Laguerre,<sup>7</sup> Aline Guillot,<sup>8</sup>  
Florence Joly,<sup>9</sup> Sophie Abadie-Lacourtoisie,<sup>10</sup> Lionnel Geoffrois,<sup>11</sup> Frédéric Di Fiore,<sup>12</sup>  
Guilhem Roubaud,<sup>13</sup> Philippe Barthélémy,<sup>14</sup> Eric Voog,<sup>15</sup> Sheik Emambux,<sup>16</sup>  
Camille Serrate,<sup>17</sup> Carolina Saldana,<sup>18</sup> Thierry Nguyen-Tan-Hon,<sup>19</sup> Yohann Loriot,<sup>20</sup>  
Jean-Christophe Eymard,<sup>21</sup> Olivier Huillard,<sup>22</sup> Frédéric Rolland,<sup>23</sup> Nadine Houédé,<sup>24</sup>  
Jean-Philippe Spano,<sup>25</sup> Mounira El Demery,<sup>26</sup> Sabine Vieillot,<sup>27</sup> Tifenn L'Haridon,<sup>28</sup>  
Werner Hilgers,<sup>29</sup> Yves Allory,<sup>30</sup> Christian Pfister,<sup>31</sup> for the VESPER Trial Investigators\*

<sup>1</sup> Department of Medical Oncology, Saint-Louis Hospital, AP-HP, Faculté de Paris, France

<sup>2</sup> North-West Canceropole Data Center, Baclesse Cancer Center, Caen, France

<sup>3</sup> Department of Medical Oncology, Paoli-Calmette Institute, Marseille, France

<sup>4</sup> Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France

<sup>5</sup> Department of Medical Oncology, ICR-IUCT Oncopole, Toulouse, France

<sup>6</sup> Department of Medical Oncology, Jean Perrin Cancer Center, Clermont-Ferrand, France

<sup>7</sup> Department of Medical Oncology, Eugène Marquis Cancer Center, Rennes, France

<sup>8</sup> Department of Medical Oncology, Lucien Neuwirth Cancer Institute, St Priest en Jarez, France

<sup>9</sup> Department of Medical Oncology, Baclesse Cancer Center, Caen, France

<sup>10</sup> Department of Medical Oncology, Institut de cancérologie de l'Ouest, Angers, France

<sup>11</sup> Department of Medical Oncology, Lorraine-Alexis Vautrin Cancer Institute, Nancy, France

<sup>12</sup> Digestive and uro-oncology Unit, Charles Nicolle University Hospital, Rouen, France

<sup>13</sup> Department of Medical Oncology, Bergonié Institute, Bordeaux, France

<sup>14</sup> Department of Medical Oncology, University Hospital, Strasbourg, France

<sup>15</sup> Victor Hugo Clinic, Le Mans, France

<sup>16</sup> Department of Medical Oncology, University Hospital, Poitiers, France

<sup>17</sup> Department of Medical Oncology, Diaconesses Croix Saint-Simon Hospital, Paris, France

<sup>18</sup> Department of Medical Oncology, Henri Mondor University Hospital, AP-HP, Créteil, France

<sup>19</sup> Department of Medical Oncology, University Hospital, Besançon, France

<sup>20</sup> Department of Cancer Medicine, Gustave Roussy, Inserm U981, Villejuif, France

<sup>21</sup> Department of Medical Oncology, Jean Godinot Institute, Reims, France

<sup>22</sup> Department of Medical Oncology, Cochin Port-Royal University Hospital, AP-HP Centre, Paris, France

<sup>23</sup> Department of Medical Oncology, West County Cancer Institute, Nantes

<sup>24</sup> Gard Cancer Institute, University Hospital, Nîmes, Inserm U1194 Montpellier Cancer Institute, Montpellier University, France

<sup>25</sup> Department of Medical Oncology, Pitié Salpêtrière University Hospital, AP-HP-SU, IUC, Paris, France

<sup>26</sup> Cap d'Or Clinic, La Seyne sur Mer, France

<sup>27</sup> Saint-Pierre Clinic, Perpignan, France

<sup>28</sup> Vendée Regional Hospital, La Roche-sur-Yon, France

<sup>29</sup> Uro-Oncology Unit, Sainte Catherine Institute, Avignon, France

<sup>30</sup> Department of Pathology, Curie Institute, Saint-Cloud, France

<sup>31</sup> Department of Urology and Clinical Investigation Center, Inserm 1404, Charles Nicolle University Hospital, Rouen, France

**Corresponding author**

Stéphane Culine  
Department of Medical Oncology  
Saint-Louis Hospital  
1, avenue Claude Vellefaux  
75010 – Paris  
France  
Phone : 33 142 494 247  
stephane.culine@aphp.fr

## **Abstract**

**A deep analysis of data from a randomized trial of perioperative chemotherapy in muscle-invasive bladder cancer shows that a minimum number of 4 cycles is required to optimize the chances of pathological complete response at cystectomy. Increasing the number beyond 4 cycles does not lead to a clinically significant deterioration in renal function without obvious gain on pathological complete response.**

**Background:** Cisplatin-based combination chemotherapy before surgery is the standard of care for muscle-invasive bladder cancer. However, the optimal chemotherapy modalities have not been precisely defined to date.

**Patients and Methods:** In the VESPER trial, patients received after randomization either gemcitabine and cisplatin (GC, 4 cycles) or methotrexate, vinblastine, doxorubicin and cisplatin (dose dense [dd]-MVAC, 6 cycles). Creatinine clearance (CrCl) was calculated before each cycle according to the Cockcroft and Gault formula. Definition criteria for local control after neoadjuvant chemotherapy included pathological complete response (ypT0N0), pathological downstaging (<ypT2N0) and organ-confined disease (<ypT3N0) at cystectomy. Baseline and treatment characteristics were studied in multivariate logistic models to determine their potential role for each type of pathological responses.

**Results:** A total of 2,128 cycles of chemotherapy were delivered, including 2,120 (99.6%) with cisplatin. Full doses of cisplatin were given in 1866 (88%) cycles. Twenty-three (4.7%) patients had to stop chemotherapy (12 GC, 11 dd-MVAC) because of renal failure. No difference in CrCl median values was observed between the two regimens during the first four cycles. A mild decrease occurred thereafter in patients treated with two additional cycles of dd-MVAC. A minimum total dose of 270 mg/m<sup>2</sup> for cisplatin was mandatory to optimize pathological complete responses.

**Conclusion:** At least 4 cycles of cisplatin-based chemotherapy should be delivered before cystectomy. Increasing the number of cycles beyond 4 cycles does not lead to a clinically significant deterioration in renal function but without obvious gain on local control.

**Key words:** Muscle-invasive bladder cancer, cisplatin-based chemotherapy, neoadjuvant treatment, pathological complete response

## Introduction

Primary surgical management of muscle-invasive bladder cancer (MIBC) with radical cystectomy and extended pelvic lymph node dissection can usually cure 50% of patients. Neoadjuvant cisplatin-based combination chemotherapy (NAC) before surgery has demonstrated a survival benefit based on level 1 evidence, with regimens including cisplatin, methotrexate, vinblastine with (MVAC) or without (CMV) doxorubicin.<sup>1-3</sup> However due to significant toxicities, alternative combinations such as dose dense MVAC (dd-MVAC) and gemcitabine-cisplatin (GC) have been proposed over the last two decades. Although different retrospective studies suggested better outcomes with dd-MVAC,<sup>4,5</sup> no prospective randomized trial comparing the respective impact on survival of dd-MVAC and GC had been reported so far. In the phase III VESPER trial recently conducted by The French Genitourinary Tumor Group (GETUG), patients received either regimen after randomization. More severe asthenia, gastrointestinal side effects and anemia along with a higher control rate were observed in the dd-MVAC arm.<sup>6</sup> In the present report, the authors focused on renal function during chemotherapy and investigated the role of cisplatin delivery (total dose, dose intensity) on local control rate.

## **Patients and Methods**

### ***Patients and chemotherapy protocol***

As previously described, 500 MIBC patients were included in the VESPER trial from February 2013 to March 2018 in 28 French participating centres after informed signed consent (Clinical trial registry: clinicaltrials.gov - NCT 018 12369).<sup>6</sup> Key inclusion criteria were histologically confirmed muscle-invasive urothelial carcinoma and disease defined by a cT2, cT3 or cT4a N0 (lymph node  $\leq$  10 mm on CT scan) M0 staging for patients receiving NAC or pT3 or pT4 or pN+ regardless of pT stage and M0 for patients receiving adjuvant chemotherapy.

Patients received after randomization either gemcitabine 1250 mg/m<sup>2</sup> on day 1 and day 8 and cisplatin 70 mg/m<sup>2</sup> on day 1 every 3 weeks for a total of 4 cycles (GC regimen) or methotrexate 30 mg/m<sup>2</sup> on day 1, vinblastine 3 mg/m<sup>2</sup> on day 2, doxorubicin 30 mg/m<sup>2</sup> on day 2 and cisplatin 70 mg/m<sup>2</sup> on day 2 with G-CSF from day 3 to day 9, every 2 weeks for a total of 6 cycles (dd-MVAC regimen). In both arms, creatinine clearance (CrCl) was calculated before each cycle according to the Cockcroft and Gault (CG) formula:  $CrCl = (140 - \text{age}) \times (\text{weight in kg}) \times (0.85 \text{ if female}) / (72 \times \text{serum creatinine})$ . A CrCl of 50 mL/min or more was required to enter the trial and start chemotherapy with full standard doses. The following adaptations were done in subsequent cycles for cisplatin according to CrCl:  $\geq 60$  mL/min, 70 mg/m<sup>2</sup>; between 50 and 59 mL/min, 50 mg/m<sup>2</sup>; between 40 and 49 mL/min: 40 mg/m<sup>2</sup>;  $< 40$  mL/min: end of treatment. Regarding neutropenic fever or other grade  $\geq 3$  toxicities, a 15% dose reduction was done for all drugs in both arms. In the absence of toxicity recovery within 14 days, or in case of grade 4 toxicity despite a dose reduction of 15%, chemotherapy was stopped.

Renal impairment during chemotherapy was defined by the threshold of a CrCl requiring cisplatin dose reduction, i.e.  $< 60$  mL/min. The following criteria were used for efficacy on

bladder cancer: pathological complete response (pCR or ypT0N0 stage), pathological downstaging (<ypT2N0 stage) and organ-confined disease (<ypT3N0 stage) at cystectomy.

### ***Statistical methods***

The diagram shown in Figure 1 issues the sample sizes for the analyses of the two endpoints discussed in the present study, i.e. renal impairment-free survival and pathological responses. As regards descriptive results, qualitative data were reported as frequency and percentage, quantitative data as either means and standard deviation or as median and 95% range depending on the normal distribution assessment of the variable. Renal impairment-free survival was computed throughout chemotherapy with an event defined as a CrCl < 60 mL/min and a time of origin at D1 of the first cycle of chemotherapy. Patients with a clearance of creatinine < 60 mL/min at the baseline were excluded from this analysis. First, survival was computed by subgroups with Kaplan-Meier method. Curves are presented with 95% confidence interval adjusted with a Locally Weighted Regression and Smoothing Scatterplots (LOWESS) method. Then, covariates joint effects were analyzed in a Cox proportional hazard model with covariates backward selection on Akaike information criterion. Probabilities of complete response, pathological downstaging and organ-confined disease after NAC were analyzed on multivariate logistic models with covariates stepwise selection on Akaike information criterion. Considering the strong correlation between chemotherapy arm and the planned dose of cisplatin, an interaction term was introduced into these models, which made it possible to describe the effect of the dose of cisplatin in each arm. All statistical analysis were performed with R statistical software v3.6.2 (R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria).



## **Results**

### ***Patients' characteristics***

Baseline characteristics of the 493 patients retained in the intent-to-treat analysis are reported in Table 1. Median age was 63 years (range, 33-80). According to body mass index (BMI), 40% and 19% of patients were classified as overweight or obese, respectively. Most patients were smokers or former smokers, 38% of patients had hypertension and 6.9% a history of coronary heart disease. Median CrCl was 87 mL/min (range, 51-152). Ten percent of patients had a calculated CrCl below 60 mL/min. Most patients received chemotherapy in the neoadjuvant setting (89% of cases). Characteristics were generally well balanced between the two arms, although the percentage of patients with diabetes was higher in the GC arm ( $p=0.026$ ).

### ***Cisplatin delivery***

A total of 2,128 cycles of chemotherapy were delivered during the study, including 2,120 (99.6%) with cisplatin (Table 2). Thirty-one patients did not received cytotoxic doses according to their real body surface area (BSA) value since local investigators capped BSA at 2 m<sup>2</sup> in 25 patients, 2.1 m<sup>2</sup> in 1 patient and 2.2 m<sup>2</sup> in 5 patients. Full doses of cisplatin were given in 1866 (88%) cycles and 23 (4.7%) patients had to stop chemotherapy (12 GC and 11 dd-MVAC) because of renal failure. Five of them (22%) had a CrCl less than 60 mL/min at the onset of chemotherapy. In the GC arm, the median number of cycles was 4 regardless of the setting (neoadjuvant or adjuvant). However, the median total dose of cisplatin was significantly lower in patients who received adjuvant chemotherapy ( $p=0.002$ ). In the dd-MVAC arm, the median numbers of cycles were 6 and 5 in the neoadjuvant and adjuvant setting, respectively, without any significant difference regarding the median total dose and dose intensity of cisplatin.

### ***Changes in creatinine clearance during treatment***

Figure 1 underlines serial changes in CrCl during chemotherapy in the whole population and according to treatment arms and baseline CrCl values. No difference in CrCl median values was observed between the two regimens during the first four cycles. A mild decrease occurred thereafter in patients treated with two additional cycles of dd-MVAC. Renal impairment-free survival curves are shown in Figure 2. Among baseline characteristics, age  $\geq 60$ , BMI  $< 20$  and CrCl between 60 and 90 retained significant prognostic value for the occurrence of renal impairment during chemotherapy (Table 3).

### ***Impact of cisplatin delivery on pathological responses***

Among 437 patients who received NAC, 397 of them (91%) underwent cystectomy. Pathological complete response, pathological downstaging and organ-confined disease status were observed in 155 (39%), 224 (56%) and 278 (70%) patients, respectively. Baseline and treatment delivery characteristics were studied in multivariate logistic models to determine their potential role for each type of pathological responses (Table 4). Obese patients had a higher rate of complete pathological response. As previously reported, treatment arm had a significant, independent prognostic value with better efficacy of dd-MVAC regarding pathological downstaging and organ-confined disease status. No evidence for an additional effect of dose intensity on disease control was observed. In the GC arm, patients who received 4 cycles clearly achieved better outcomes as compared to patients who received 3 cycles or less for all types of pathological responses. In the dd-MVAC arm, increasing the number of cycles beyond four did not appear to provide statistically higher local control rates.

## Discussion

Cisplatin has emerged as a major cytotoxic agent in urothelial tract tumors in the late 70s.<sup>7</sup> As single agent, cisplatin was initially reported to produce response rates as high as 40%, but prospective randomized trials failed to confirm these results and complete responses were rarely observed. Although essentially palliative for patients with metastatic disease, the benefit of chemotherapy on response rates and overall survival was subsequently reported through the development of cisplatin-based combination regimens such as MVAC or CMV.<sup>8,9</sup> Then their use in the perioperative setting led to establish NAC and radical cystectomy as current standard of care for MIBC.<sup>1-3</sup>

Given the potential for renal toxicity with cisplatin-based chemotherapy, adequate renal function is a prerequisite, with a common eligibility threshold of measured or calculated CrCl of  $\geq 60$  mL/min in clinical trials or medical oncologist community surveys.<sup>10</sup> However, no formal consensus has been established and robust data did not exist to support a specific renal function threshold and an optimal methodology to assess eligibility for as well as dose adaptations of cisplatin throughout therapy in MIBC. Regarding cisplatin eligibility, many contradictory results have been reported according to methods used for CrCl evaluation. In a retrospective study including 116 patients, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was more likely to deem a patient eligible for cisplatin compared with the CG formula, especially beyond 70 years of age.<sup>11</sup> Another study found no difference between CDK-EPI equation, CG formula and the Modified Diet in Renal Disease (MDRD) equation, except for the subset of patients age  $> 80$  in whom the CDK-EPI equation identified a much smaller proportion of cisplatin-eligible patients.<sup>12</sup> Finally, in a third, retrospective study including 208 patients who received MVAC for advanced bladder cancer, concordance between calculated and measured CrCl was low, especially in those older than

65 years. The ability to complete at least 3 cycles of MVAC was related to a measured CrCl more than 60 mL/min, but not to a calculated CrCl more than 60 mL/min.<sup>13</sup>

In the VESPER trial, the CG formula was used both for cisplatin eligibility (with 50 mL/min as threshold) and cisplatin dose adjustments throughout chemotherapy cycles. The present report confirms the relevance of this approach. Indeed, full doses of cisplatin were given in the majority of scheduled cycles (88%) and only 23 patients (4.7%) had to stop treatment because of renal failure. Moreover, 50 patients (10%) were included with a measured CrCl below 60 mL/min and only 10% of them had to stop chemotherapy because of renal failure. A trend towards poorer cisplatin delivery was observed in the adjuvant setting, with a lower median total dose of cisplatin in the GC arm and a reduced median number of cycles in the dd-MVAC arm. However, the number of patients who were treated in the adjuvant setting remains too small to draw firm conclusions. As the optimal number of cycles in the perioperative setting is still unknown, it is important to emphasize that increasing the number of cycles to six in the dd-MVAC arm did not lead to a clinically significant deterioration in renal function. Without major surprise, older age ( $\geq 70$  years), low BMI ( $< 20$  kg/m<sup>2</sup>) and baseline CrCl  $< 90$  mL/min were identified as independent prognostic variable for occurrence of renal impairment and therefore cisplatin dose modifications during chemotherapy.

In patients who are treated with NAC, achieving pCR in the bladder and lymph nodes at surgery has been shown to be a strong surrogate for survival outcomes.<sup>1,14-16</sup> It has been also suggested that pathologic downstaging was associated with improved survival.<sup>17,18</sup> In the VESPER trial, we observed no significant difference in the complete pathologic response rate between the two arms but higher pathologic downstaging and higher organ-confined disease rates in the dd-MVAC arm.<sup>6</sup> Our prospective randomized data offered the possibility to refine the potential relationship between patients' baseline characteristics, cisplatin delivery and

pathologic responses. BMI  $\geq$  25 kg/m<sup>2</sup> and a minimum number of cycles of 4 cycles of chemotherapy were identified as independent prognostic variables regarding pCR at surgery. The influence of BMI for patients treated with NAC for MIBC was recently studied in a retrospective, single institution experience.<sup>19</sup> Toxicity and efficacy of NAC were compared between obese patients receiving chemotherapy based on capping at a body-surface area of 2.2 m<sup>2</sup> and healthy weight patients. Obese patients were individually paired with normal BMI patients sharing similar clinical and biological characteristics. The pCR rate was similar in both groups. In the VESPER trial, 31 (6.3%) patients did not receive optimal cytotoxic doses since BSA was capped by local investigators. Therefore, a lower pCR rate related to a potential drug underdosing could have been expected in obese patients. The opposite observation might be related to sarcopenic obesity. However, sarcopenia has previously been linked to renal impairment and prognosis after NAC,<sup>20,21</sup> but not to pathological response.<sup>20,22</sup> Moreover, we did not observe a higher myelosuppression suggesting greater exposure due to weight-based dose calculation in obese patients.

The optimal number of NAC cycles remains undefined. A survival benefit for 3 cycles of MVAC or CMV is supported by level 1 evidence.<sup>1-3</sup> Alternative combinations with 3 to 4 cycles of dd-MVAC were reported in 2 phase II trials.<sup>23-24</sup> The pCR rates (26% and 38% after 4 and 3 cycles, respectively) were roughly similar to that observed in the VESPER trial (42%). Our data strongly argue for a lesser chance of obtaining a pCR when less than 4 cycles of GC or dd-MVAC are delivered. However, increasing the number of cycles beyond four did not appear to provide statistically higher local control rates.

In conclusion, prospective data from the VESPER trial provide answers as to the optimal number of cisplatin-based chemotherapy cycles in the neoadjuvant setting for patients with MIBC. A minimum number of 4 cycles is required to optimize the chances of getting a pCR at

cystectomy after NAC. Increasing the number to 6 cycles does not lead to a clinically significant deterioration in renal function but the benefit on patients' survival remains to be proven.

**Funding**

The GETUG/AFU V05 VESPER randomized phase III study was supported by a grant from the French Ministry of Health (PHRC 2011-037).

**Sponsor**

The sponsor of the study was the University Hospital in Rouen, France.

**Disclosure**

Authors have declared no conflicts of interest.

**Acknowledgements**

The authors strongly thank Cécile Pourcher, Frédérique Caillot and Assia Ferrane, Rouen University Hospital Clinical Research Assistants, for their active participation in the multicenter monitoring of this phase III trial.

The Northwest Data Center (CTD-CNO) is acknowledged for managing the data. It is supported by grants from the French National League against Cancer (LNC) and the French National Cancer Institute (INCa).

We also thank all urologists who were involved in the trial: G. Pignot (Marseille), J.P. Fendler (Lyon), M. Soulié (Toulouse), L. Guy (Clermont-Ferrand), G. Verhoest (Rennes), N. Mottet (Saint-Etienne), A. Doerfler (Caen), A.R. Azzouzi (Angers), P. Mongiat-Artus (Paris, Saint-Louis), P. Eschwege (Nancy), J.L. Hoepffner (Bordeaux), H. Lang (Strasbourg), E. Mandron (Le Mans), A. Colau (Paris, Diaconesses), A de La Taille (Créteil), F. Kleinclaus (Besançon), J. Irani (Villejuif), S. Larre (Reims), M. Zerbib (Cochin), J. Rigaud (Nantes), S. Droupy (Nimes), M. Roupret (Paris), C. Legon (La Seyne sur Mer), N. Letang (Perpignan), N. Gaschignard (La Roche sur Yon), J.L. Davin (Avignon)<sup>†</sup>.

## References

1. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. *N Engl J Med* 2003;349:859-66.
2. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. *Eur Urol* 2005;48:202-6.
3. International collaboration of trialists. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. *J Clin Oncol* 2011;29:2171-7.
4. Zargar H, Shah JB, van Rhijn BW, et al. Neoadjuvant dose dense MVAC versus gemcitabine and cisplatin in patients with cT3-4aN0M0 bladder cancer treated with radical cystectomy. *J Urol* 2018;199:1452-8.
5. Peyton CC, Tang D, Reich RR, et al. Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer. *JAMA Oncol* 2018;4:1535-42.
6. Pfister C, Gravis G, Fléchon A, et al. Randomized phase III of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with muscle-invasive bladder cancer (MIBC). Analysis of the GETUG/AFU V05 VESPER trial secondary end-points: chemotherapy toxicity and pathological responses. *Eur Urol* 2021;79 :214-21.
7. Yagoda A, Watson RC, Gonzales-Vitale JC, et al. Cis-dichlorodiammineplatinum (II) in advanced bladder cancer. *Cancer Treat Rep* 1976;60:917-23.



8. Loehrer P, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group study. *J Clin Oncol* 1992;10:1066-73.
9. Mead GM, Russell M, Clark P, et al. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. *Br J Cancer* 1998;78:1067-75.
10. Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. *Lancet Oncol* 2011;12:211-4.
11. Tsao CK, Moshier E, Seng SM, et al. Impact of the CDK-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer. *Clin Genitourinary Cancer* 2012;10:15-20.
12. Pal SK, Ruel N, Villegas S, et al. CKD-EPI and Cockcroft-Gault equations identify similar candidates for neoadjuvant chemotherapy in muscle-invasive bladder cancer. *Plos One* 2014;9:e94471.
13. Raj GV, Iasonos A, Herr H, Donat SM. Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. *J Clin Oncol* 2006;24:3095-100.
14. Kassouf, W, Spiess PE, Brown GA, et al. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. *Eur Urol* 2007;52:769-76.

15. Sonpavde G, Goldman BH, Speights VO, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. *Cancer* 2009;115:4104-9.
16. Petrelli F, Coinu A, Cabiddu M, et al. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: A meta-analysis. *Eur Urol* 2014;65:350-7.
17. Iyer G, Tully CM, Zabor EC, et al. Neoadjuvant gemcitabine-cisplatin plus radical cystectomy-pelvic lymph node dissection for muscle-invasive bladder cancer: A 12-year experience. *Clin Genitourinary Cancer* 2020;18:387-94.
18. Splinter TA, Scher HI, Denis L, et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. *J Urol* 1992;147:606-8.
19. Belaube N, Dumont C, Bonnet C, et al. Neoadjuvant chemotherapy for urothelial muscle-invasive bladder cancer: influence of body mass index on efficacy and toxicity. *Clin Onco* 2021;4:1-4.
20. Lyon TD, Frank I, Takahashi N, et al. Sarcopenia and response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. *Clin Genitourinary Cancer* 2019;17:216-22.
21. Régnier P, De Luca V, Brunelle S, et al. Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy and post cystectomy complications. *Minerva Urol Nefrol* Feb 19. doi: 10.23736/S0393-2249.20.03616-4. Online ahead of print.

22. Stangl-Kremser J, Mari A, D'Andrea D, et al. Sarcopenia as a predictive factor for response to upfront cisplatin-based chemotherapy in patients with muscle-invasive urothelial bladder cancer. *Urol Int* 2018;101:197-200.
23. Choueiri TK, Jacobus S, Bellemut J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin and cisplatin with pegfilgrastim support in muscle invasive urothelial cancer: Pathologic, radiologic and biomarker correlates. *J Clin Oncol* 2014; 32:1882-94.
24. Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin and cisplatin is safe, effective and efficient neoadjuvant treatment for muscle invasive bladder cancer. Results of a multicenter phase II study with molecular correlates of response and toxicity. *J Clin Oncol* 2014;32:1895-901.

**Table 1 – Baseline patients' characteristics**

<b>Variable</b>	<b>GC (N=245)</b>	<b>dd-MVAC (N=248)</b>	<b>Total (N=493)</b>
<b>Age, years, No (%)</b>			
<60	75 (31)	82 (33)	157 (32)
60-69	119 (49)	124 (50)	243 (49)
≥70	51 (21)	42 (17)	93 (19)
<i>Mean (standard deviation)</i>	63 (7.6)	62.6 (7.9)	62.8 (7.7)
<b>Sex, No (%)</b>			
Male	206 (84)	202 (81)	408 (83)
Female	39 (16)	46 (19)	85 (17)
<b>Body mass index, kg/m<sup>2</sup>, No (%)</b>			
<18.5	3 (1.2)	9 (3.6)	12 (2.4)
18.5-<25	95 (39)	95 (38)	190 (39)
25-<30	100 (41)	99 (40)	199 (40)
≥30	47 (19)	45 (18)	92 (19)
<i>Mean (standard deviation)</i>	26.6 (4.7)	26.0 (4.4)	26.3 (4.5)
<b>Body surface area (m<sup>2</sup>)</b>			
<i>Mean (standard deviation)</i>	1.9 (0.2)	1.9 (0.2)	1.9 (0.2)
<b>Medical history, No (%)</b>			
Tobacco	198 (84)	197 (81)	395 (80)
Hypertension	100 (41)	89 (36)	189 (38)
Coronary artery disease	13 (5.3)	19 (7.7)	32 (6.5)
Diabetes	14 (5.7)	4 (2)	18 (4)
<b>Performance status, No (%)</b>			
0	171 (70)	165 (67)	336 (68)
1	72 (29)	82 (33)	154 (31)
Unknown	2 (0.8)	1 (0.4)	3 (0.6)
<b>Hemoglobin (g/dL)</b>			
<i>Median (95% range)</i>	14.1 (10.7-16.5)	14.0 (11.0-16.5)	14.0 (10.8-16.5)
<b>Alkaline phosphatases (UI/L)</b>			
<i>Median (95% range)</i>	73 (46-138)	73 (42-148)	73 (45-146)
<b>Total bilirubin (mg/L)</b>			
<i>Median (95% range)</i>	4.4 (1.8-11.0)	4.7 (2.0-11.0)	4.7 (1.8-11)
<b>Serum creatinine (mg/L)</b>			
<i>Median (95% range)</i>	9 (6-14)	9 (5-14)	9 (5-14)
<b>Creatinine clearance, mL/min, No (%)</b>			
50-59	27 (11)	23 (9.3)	50 (10)
60-89	113 (46)	107 (43)	220 (45)
≥90	105 (43)	118 (48)	223 (45)
<i>Median (95% range)</i>	86 (52-157)	88.5 (51-147)	87 (51-152)

**Table 2 – Cisplatin delivery**

	<b>Neoadjuvant chemotherapy</b>		<b>Adjuvant chemotherapy</b>	
	GC (N=219)	dd-MVAC (N=218)	GC (N=26)	dd-MVAC N=(30)
<b>Number of cycles</b> <i>Median (range)</i>	4 (1-4)	6 (0-6)	4 (1-4)	5 (1-6)
Total	803	1093	92	140
Total with cisplatin	803	1087	91	139
Total with full doses of cisplatin (%)	745 (93)	926 (85)	73 (80)	122 (88)
<b>Total dose (mg)</b> <i>Median (95% range)</i>	522 (134-608)	700 (132-895)	454 (125-579)	675 (131-843)
<b>Dose intensity (mg/m<sup>2</sup>/week)</b> <i>Median (95% range)</i>	22.9 (16.9-24.1)	31.8 (20.5-35.7)	21.9 (14.6-23.8)	33.8 (21.5-35.2)
<b>Relative dose intensity</b>	98%	91%	94%	97%

**Table 3 – Cox proportional hazard model for renal impairment during chemotherapy**

<b>Baseline characteristics</b>	<b>Hazard ratio (95% CI)</b>	<b>p value</b>
<b>Age (years)</b>		
< 60	-	
60-69	2.37 (1.21-4.64)	0.012
≥ 70	4.85 (2.27-10.4)	< 0.001
<b>Body mass index (kg/m<sup>2</sup>)</b>		
< 20	3.20 (1.43-7.15)	0.005
20-<25	-	
25-<30	0.82 (0.48-1.41)	0.5
≥ 30	0.70 (0.35-1.42)	0.3
<b>Coronary artery disease</b>		
No	-	
Yes	1.82 (0.86-3.86)	0.12
<b>Creatinine clearance (mL/min)</b>		
≥ 90	-	
60-89	2.93 (1.69-5.10)	< 0.001
<b>Chemotherapy arm</b>		
GC	-	
dd-MVAC	1.20 (0.75-1.93)	0.5


Covariates tobacco, timing of chemotherapy (adjuvant or neoadjuvant), sex, lymph nodes involvement, diabetes, high blood pressure and OMS status were excluded in this order from the final model with the backward selection. Chemotherapy arm was forced in the selection.

**Table 4 – Logistic model for pathological responses at cystectomy**

	<b>N</b>	<b>Complete pathological response</b>		<b>Pathological downstaging</b>		<b>Organ-confined disease</b>	
		<i>Odd ratio (95% CI) p value</i>		<i>Odd ratio (95% CI) p value</i>		<i>Odd ratio (95% CI) p value</i>	
<u><i>Body mass index (kg/m<sup>2</sup>)</i></u>							
< 20	23	0.83 (0.30-2.29)	0.7	0.41 (0.16-1.10)	0.078		
20-<25	126	-		-			
25-<30	164	1.90 (1.16-3.12)	0.011	1.67 (1.03-2.73)	0.038		
≥ 30	84	1.83 (1.02-3.29)	0.043	1.29 (0.72-2.30)	0.4		
<u><i>Creatinine clearance at baseline (mL/min)</i></u>							
≥90	187					-	
60-89	174					0.64 (0.39-1.04)	0.069
50-59	36					0.28 (0.13-0.60)	0.001
<u><i>High blood pressure</i></u>							
No	237					-	
Yes	160					0.65 (0.40-1.03)	0.065
<u><i>Coronary artery disease</i></u>							
No	369			-			
Yes	28			2.05 (0.83-5.02)	0.12		
<u><i>Chemotherapy arm</i></u>							
GC	198	-		-		-	
dd-MVAC	199	1.40 (0.77-2.56)	0.3	2.06 (1.08-3.93)	0.029	2.46 (1.10-5.52)	0.028
<u><i>Cisplatin dose-intensity (mg/m<sup>2</sup>/week)</i></u>							
≥ 30	218	-		-		-	
25-30	46	1.04 (0.50-2.18)	0.9	0.71 (0.33-1.51)	0.4	0.75 (0.31-1.79)	0.5
< 25	132	1.06 (0.37-3.02)	0.9	0.84 (0.30-2.39)	0.7	0.75 (0.22-2.60)	0.7
<u><i>Total dose of cisplatin (mg/m<sup>2</sup>)</i></u>							
<i>GC arm</i>							
≥ 270 (4 cycles)	134	-		-		-	
< 270	64	0.46 (0.23-0.89)	0.022	0.49 (0.26-0.91)	0.024	0.47 (0.25-0.88)	0.019
<i>dd-MVAC arm</i>							
≥ 410 (6 cycles)	65	-		-		-	
340 to 410 (5 cycles)	62	0.56 (0.27-1.15)	0.12	0.61 (0.28-1.29)	0.19	0.89 (0.33-2.37)	0.8
270-340 (4 cycles)	38	0.85 (0.38-1.93)	0.7	0.67 (0.28-1.59)	0.4	0.44 (0.16-1.20)	0.11
< 270 (< 4 cycles)	34	0.67 (0.28-1.58)	0.4	0.55 (0.23-1.32)	0.18	0.39 (0.14-1.10)	0.074

Covariates age, sex, OMS status, cT tumor stage, tobacco, diabetes were excluded from each final model with the stepwise selection. Chemotherapy arm and its interaction with total dose of cisplatin were forced in the selections.

**Figure 1 – Flow diagram from enrollment to end of primary treatment**






**Figure 2 – Evolution of median creatinine clearance from baseline to the end of chemotherapy**

Whole patient sample (A), According to treatment arms (B) According to baseline creatinine clearance (C).

For A and B, the q1-q3 interval is presented with a colored area. For each curve, the number of patients assessed at the baseline is indicated, then for each cycle the percentage of these patients whose creatinine clearance was evaluated.



### Figure 3 – Renal impairment-free survival curves

Kaplan-Meier curves with 95% confidence area according to treatment arms (A, N=493) and according to baseline creatinine clearance (B, N=443, patients with creatinine clearance < 60 mL/min at baseline are not presented).

